Big Questions in Oncology at ESMO 2026: Who Decides the Future of Cancer Care?
OncoDaily Grand Rounds at ESMO 2026: Key Discussions and Clinical Perspectives on Bladder Cancer, Part 1
25 Posts Not to Miss from ESMO Congress 2026: Day 3
Expert Discussion at COGC 2026: Can Community Oncology Deliver More Without Moving the Patient?
Charles Kelley Cancer Diagnosis at 45: Multiple Myeloma Symptoms, Treatment & Prognosis
Pat Soon-Shiong: A New Chapter in Medical Publishing Begins With the Launch of a New Journal at ESMO26
Lidia Trombello: ESMO 2026 Update - Phase III postMONARCH Overall Survival Results
AZUR-1 at ESMO 2026: Dostarlimab monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
